
Sanofi Consumer Healthcare India Q2 Results FY27: PAT Rises 21.78% to Rs 76.60 Cr, Revenue Rs 263.10 Cr
Updated: 28 Oct 2026 • 7:08 pm
Posted by:

Quick Answer
Sanofi Consumer Healthcare India Q2 Results FY27 were declared on 28 October 2026 on a Standalone basis. Revenue rose 12.48% YoY to Rs 263.10 Cr from Rs 233.90 Cr, while net profit rose 21.78% to Rs 76.60 Cr from Rs 62.90 Cr. Operating Profit stood at Rs 101.70 Cr in these quarterly results.
Sanofi Consumer Healthcare India Ltd (SANOFICONR) Q2 Results FY27 announced on 28 October 2026, covering the company's financial performance for the July to September quarter. The results date brought standalone revenue of Rs 263.10 Cr and net profit (PAT) of Rs 76.60 Cr. Sanofi Consumer Healthcare India Q2 Results FY27 therefore pair a rise in sales with a faster rise in profit, and these standalone results frame the analysis below.
This results analysis of Sanofi Consumer Healthcare India Q2 Results covers the financial highlights, business drivers, outlook and risks. It begins with the Financial Highlights table, assembled from the figures Univest tracks for each listed company as it reports.
Click Here – Get Free Investment Predictions
Sanofi Consumer Healthcare India Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 263.1 Cr | Rs 233.9 Cr | +12.48% YoY |
| Operating Profit | Rs 101.7 Cr | Rs 85 Cr | +19.65% YoY |
| Net Profit (PAT) | Rs 76.6 Cr | Rs 62.9 Cr | +21.78% YoY |
Source: company filing for Sanofi Consumer Healthcare India Q2 Results FY27, 28 October 2026. Figures in Rs Crore, Standalone basis.
Key Takeaways from Sanofi Consumer Healthcare India Q2 Results: What Stands Out
- Revenue YoY growth of 12.48%: standalone revenue reached Rs 263.10 Cr against Rs 233.90 Cr in the same quarter of last year.
- Net profit up 21.78%: Sanofi Consumer Healthcare India Q2 Results FY27 show net profit of Rs 76.60 Cr compared with Rs 62.90 Cr a year earlier, a gain of Rs 13.70 Cr.
- Operating Profit Rs 101.70 Cr: this line rose 19.65% YoY from Rs 85.00 Cr, a gain of Rs 16.70 Cr that moved with net profit.
- Margin gain: net profit margin improved to 29.1% from 26.9% in the comparison quarter, so profit grew faster than sales.
- Return on equity: the full-year figure was 73.20% in FY25, a very high level that nonetheless declined from the year before.
Sanofi Consumer Healthcare India Q2 Results FY27: Performance Analysis
Sanofi Consumer Healthcare India Q2 Results FY27 show standalone revenue of Rs 263.10 Cr, up 12.48% from Rs 233.90 Cr, while net profit rose 21.78% to Rs 76.60 Cr from Rs 62.90 Cr. Operating Profit of Rs 101.70 Cr was 19.65% higher than the Rs 85.00 Cr recorded a year earlier. Profit therefore grew faster than sales.
Within Sanofi Consumer Healthcare India Q2 Results FY27, the size of each change is the central point of the results analysis. Revenue added Rs 29.20 Cr YoY, Operating Profit added Rs 16.70 Cr and net profit added Rs 13.70 Cr. A wider net profit margin of 29.1%, against 26.9% a year earlier, links these moves in the standalone statement.
Investors tracking Sanofi Consumer Healthcare India Q2 Results will see that all three lines moved in the same direction. Revenue, Operating Profit and net profit each rose YoY, so the results analysis records a quarter of broad improvement on the standalone statement.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points first to revenue, which grew 12.5% year on year to Rs 263.10 Cr in the latest quarter. This is the disclosed top-line factor behind the standalone figures.
Profit Growth – Net profit rose 21.8% year on year to Rs 76.60 Cr, and the net profit margin improved to 29.1% from 26.9% in the comparison quarter. Each rupee of sales therefore left more profit than a year earlier.
High Return on Equity – Return on equity was 73.20% in FY25. This full-year ratio describes how much profit the business earned on shareholder funds before the latest quarter.
FY27 Outlook After Sanofi Consumer Healthcare India Q2 Results
Full-year FY27 results for Sanofi Consumer Healthcare India will turn on the quarters still to be reported, and the July to September 2026 period is one input. On a results analysis basis, Rs 76.60 Cr of net profit sets the comparison for the next filing.
Sanofi Consumer Healthcare India Q2 Results FY27 leave two reference points for the rest of the year: revenue growth of 12.48% and net profit growth of 21.78%. Investors can follow later disclosures on the Univest Screener and the Univest app, which brings the discussion to the risks.
Key Risks to Watch After Sanofi Consumer Healthcare India Q2 Results FY27
Lower Annual Profit Per Share
Annual profit per share has slipped between FY23 and FY25. Sanofi Consumer Healthcare India Q2 Results FY27 show a strong quarter, so investors will watch whether later filings reverse this multi-year slide.
Lower Return on Equity
Return on equity declined to 73.20% in FY25 from 79.28% in FY24. This full-year drop is the background to the latest quarter, and later filings will show whether the return recovers.
Lower Return on Capital Employed
Return on capital employed declined to 98.11% in FY25 from 104.33% in FY24. This is the matching measure on total capital, and the next annual filing will show where it settles.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Sanofi Consumer Healthcare India Q2 Results FY27 show standalone revenue of Rs 263.10 Cr and net profit of Rs 76.60 Cr, which means higher sales and higher profit in the quarterly results. The moves are on record as standalone results in the filing dated 28 October 2026. Anyone reading Sanofi Consumer Healthcare India Q2 Results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Sanofi Consumer Healthcare India Q2 Results FY27
What are Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. Sanofi Consumer Healthcare India Q2 Results FY27 are the Standalone July to September 2026 results of Sanofi Consumer Healthcare India, with revenue of Rs 263.10 Cr and net profit of Rs 76.60 Cr, as the Quick Answer summarises.
What is the results date for Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. Sanofi Consumer Healthcare India declared the quarter on 28 October 2026, so the results date covers the July to September 2026 period, while the introduction explains the standalone basis of the figures.
What revenue was reported in Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. Sanofi Consumer Healthcare India reported standalone revenue of Rs 263.10 Cr, against Rs 233.90 Cr a year earlier, so revenue added Rs 29.20 Cr, as the Financial Highlights table shows.
What net profit was reported in Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. Sanofi Consumer Healthcare India Q2 Results FY27 show net profit of Rs 76.60 Cr against Rs 62.90 Cr in the same quarter last year, so profit rose by Rs 13.70 Cr, as the Key Takeaways section notes.
How much YoY growth did revenue show in Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. Revenue grew 12.48% YoY in the July to September quarter, from Rs 233.90 Cr to Rs 263.10 Cr, while net profit rose 21.78%, as the Performance Analysis explains.
Did net profit rise or fall in Sanofi Consumer Healthcare India Q2 Results?
Ans. Sanofi Consumer Healthcare India net profit rose 21.78% YoY to Rs 76.60 Cr from Rs 62.90 Cr, growing faster than revenue, as the Performance Analysis section discusses.
What was the Operating Profit in Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. Operating Profit was Rs 101.70 Cr, up 19.65% from Rs 85.00 Cr a year earlier, so it grew faster than the 12.48% YoY revenue growth, as the Key Takeaways section outlines.
Are Sanofi Consumer Healthcare India Q2 Results standalone results or consolidated results?
Ans. The figures are Standalone results, covering Sanofi Consumer Healthcare India as a single company, so every revenue and profit number in the article follows the standalone basis stated in the introduction.
What business factors shaped Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. The disclosed factors are revenue growth of 12.5% YoY, a 21.8% rise in net profit, a net profit margin of 29.1% against 26.9%, and a return on equity of 73.20% in FY25.
What are the key risks after Sanofi Consumer Healthcare India Q2 Results FY27?
Ans. The listed risks are a slide in annual profit per share since FY23, a return on equity that declined to 73.20% from 79.28%, and a return on capital employed down to 98.11% from 104.33%.
What is the outlook after Sanofi Consumer Healthcare India Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be reported, while Rs 76.60 Cr of quarterly net profit and 12.48% revenue growth are the reference points, as the Outlook section states.
Where can I find the complete Sanofi Consumer Healthcare India Q2 Results FY27 data?
Ans. The Financial Highlights table in this article carries the full revenue and net profit comparison, while the Univest Screener lets investors follow Sanofi Consumer Healthcare India filings alongside other listed companies.
Recent Articles

Bhagwati Autocast Q2 Results FY27: PAT Rises 9.97% to Rs 3.97 Cr, Revenue Rs 46.85 Cr
28 October 2026

Welspun Investments and Commercials Q2 Results FY27: PAT Jumps 151% to Rs 8.76 Cr, Revenue Rs 14.11 Cr
28 October 2026

Bhageria Industries Q2 Results FY27: PAT Jumps 386.05% to Rs 55.75 Cr, Revenue Rs 455.70 Cr
28 October 2026

Raymond Lifestyle Q2 Results FY27: PAT Falls 10.19% to Rs 67.53 Cr, Revenue Rs 2,075.10 Cr
28 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Bhagwati Autocast Q2 Results FY27: PAT Rises 9.97% to Rs 3.97 Cr, Revenue Rs 46.85 Cr
Welspun Investments and Commercials Q2 Results FY27: PAT Jumps 151% to Rs 8.76 Cr, Revenue Rs 14.11 Cr
Bhageria Industries Q2 Results FY27: PAT Jumps 386.05% to Rs 55.75 Cr, Revenue Rs 455.70 Cr
Raymond Lifestyle Q2 Results FY27: PAT Falls 10.19% to Rs 67.53 Cr, Revenue Rs 2,075.10 Cr
eClerx Services Q2 Results FY27: PAT Slips 1.56% to Rs 180.60 Cr, Revenue Rs 1,188.66 Cr
Popular this week
Pidilite Industries Q2 Results FY27: PAT Rises 7.16% to Rs 626.46 Cr, Revenue Rs 4,297.59 Cr

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





